<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053157_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134144</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012NZ064606</safetyreportid>
		<primarysourcecountry>NZ</primarysourcecountry>
		<occurcountry>NZ</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121211</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20120727</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121205</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012NZ064606</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>Sally</reportergivename>
			<reporterfamilyname>Davidson</reporterfamilyname>
			<reporterorganization>Tacy Street Clinic</reporterorganization>
			<reporterstreet>36 Tacy St, Kilbirnie</reporterstreet>
			<reportercity>Wellington</reportercity>
			<reportercountry>NZ</reportercountry>
			<qualification>1</qualification>
			<observestudytype>3</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>SP</patientinitial>
			<patientinvestigationnumb>ETS2090</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19650204</patientbirthdate>
			<patientweight>75</patientweight>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Affective disorder</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypothyroidism</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Psychotic disorder</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Platelet count decreased</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Moderately impaired renal function, stage 3 CKD (chronic kidney disease).</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Chronic kidney disease</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal failure chronic</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Moderately impaired renal function, stage 3 CKD (chronic kidney disease).</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Impaired renal function</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal impairment</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Creatinine level was 137 umol/L</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Creatinine blood increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood creatinine increased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120423</reactionstartdate>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>EGFR was 48 ml/min/1.73m^2</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>GFR decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Glomerular filtration rate decreased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120423</reactionstartdate>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Impaired glucose tolerance</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Glucose tolerance impaired</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Glucose tolerance impaired</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Mean platelet volume 9.5 fl</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Mean platelet volume increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Mean platelet volume increased</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120326</reactionstartdate>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Dyslipidaemia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Dyslipidaemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyslipidaemia</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Eosinophil count was 0.02x10^9/l, 02%</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Eosinophil count decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Eosinophil count decreased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20080310</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Platelets count was 126 x 10^9</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Platelet count decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Platelet count decreased</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20080310</reactionstartdate>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120423</testdate>
				<testname>Blood creatinine</testname>
				<testresult>137</testresult>
				<testunit>umol/l</testunit>
				<lowtestrange>77</lowtestrange>
				<hightestrange>119</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080310</testdate>
				<testname>Eosinophil count</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Eosinophil count</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120423</testdate>
				<testname>Glomerular filtration rate</testname>
				<testresult>48/1.73</testresult>
				<testunit>mg/m2</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Lymphocyte count</testname>
				<testresult>17</testresult>
				<testunit>%</testunit>
				<lowtestrange>20</lowtestrange>
				<hightestrange>45</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120326</testdate>
				<testname>Mean platelet volume</testname>
				<lowtestrange>5.5</lowtestrange>
				<hightestrange>9.0</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120423</testdate>
				<testname>Mean platelet volume</testname>
				<lowtestrange>5.5</lowtestrange>
				<hightestrange>9.0</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Neutrophil count</testname>
				<testresult>80</testresult>
				<testunit>%</testunit>
				<lowtestrange>40</lowtestrange>
				<hightestrange>75</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080310</testdate>
				<testname>Platelet count</testname>
				<testresult>142</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080407</testdate>
				<testname>Platelet count</testname>
				<testresult>140</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080603</testdate>
				<testname>Platelet count</testname>
				<testresult>136</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080630</testdate>
				<testname>Platelet count</testname>
				<testresult>194</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120326</testdate>
				<testname>Platelet count</testname>
				<testresult>126</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120423</testdate>
				<testname>Platelet count</testname>
				<testresult>135</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Schizophrenia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20021022</drugstartdate>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>287.5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>287.5 mg</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201103</drugstartdate>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>162.5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>162.5 mg</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201203</drugstartdate>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>AMISULPRIDE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201104</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMISULPRIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>AMISULPRIDE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>300 mg, UNK</drugdosagetext>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120403</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMISULPRIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LITHIUM</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Affective disorder</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201010</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LITHIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LITHIUM</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugstructuredosagenumb>750</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>750 mg, UNK</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2012</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LITHIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LAMOTRIGINE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Affective disorder</drugindication>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2009</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LAMOTRIGINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LAMOTRIGINE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>300 mg, UNK</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2012</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LAMOTRIGINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>THYROXINE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypothyroidism</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012NZ064606 is an initial PMS case report received from physician on 27 Jul 2012 with follow up report received from physician on 05 Dec 2012: The report refers to 47-years-old male patient (NHI No-ETS2090). The patient current condition included psychotic features, mood disorder, hypertension, hypothyroidism and platelet count decreased. The patient concomitant medication included amisulpride, lithium, lamotrigine, thyroxin (reported as possibly thyroxin because of illegible word on source document). The patient received Clozaril (clozapine) for resistant bipolar mood disorder and psychotic features at unknown dose from 22 Oct 2002. It was reported that, the dose of Clozaril was reduced from 287.5 mg (March 2011) to 162.5 mg (March 2012). The patient had decreased platelet count for more than 10 years intermittently, more persistently in last two years. It was also reported that estimated glomerular filtration rate had decreased and creatinine already had increased (reported as decreased and increased) when decision made to reintroduce lithium in late 2010. The patient had mild long standing dyslipidemia and impaired glucose tolerance increased in last year. On 10 Mar 2008, the patient laboratory data showed platelet count was 142 x 10^9/L, eosinophil count was 0.02x10^9/l. On 07 Apr 2008, platelet count was 140 x 10^9/L, eosinophil count was 0.07x10^9/l. On 03 Jun 2008, platelet count was 136 x 10^9/L and eosinophil count was 0.12x10^9/l. On 30 Jun 2008, platelet count was 194 x 10^9/L and eosinophil count was 0.12x10^9/l. On 26 Mar 2012, the patient laboratory data showed platelet count was 126 x 10^9/L, eosinophil count was 0.22x10^9/l and mean platelet volume was 9.5 fl. On 23 Apr 2012, the patient laboratory data showed mean platelet volume was 9.1 fl, platelet count was 135 x 10^9/L, creatinine levels was 137umol/L, eosinophil count was 0.16x10^9/l and estimated glomerular filtration rate was 48ml/min/1.73m^2. Reporter stated that, the patient laboratory data suggest moderately impaired renal function, stage 3 CKD (chronic kidney disease). On 03 Dec 2012 the patient laboratory data showed neutrophils count was 80% (normal range (40-75), eosinophil count was 02% and lymphocytes count was 17% (20-45). The treatment with Clozaril was continued. The seriousness criterion for the event creatinine blood increased, GFR decreased was reported as medically significant, and the seriousness criterion for the event platelet count decreased, mean platelet volume increased was reported as non-serious, while for other events seriousness criterion was not reported. The outcome for the event creatinine blood increased, GFR decreased, platelet count decreased, mean platelet volume increased was reported as ongoing, while for other events outcome was not reported. Outcome of the event eosinophil count decreased was reported as completely recovered and outcome of the event platelet count decreased was reported as condition improving. The causality for the event creatinine blood increased, GFR decreased was reported as not suspected, and the causality for the event platelet count decreased, mean platelet volume increased was reported as suspect, while for other events causality was not reported.


Follow up report received from physician on 05 Dec 2012: Laboratory data of 03 Dec 2012, outcome of the events eosinophil count decreased and platelet count decreased updated.</narrativeincludeclinical>
				<sendercomment>Based on Review of available reported data does not allow for a proper causality assessment. Reported event is unassessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
